Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome

Acute coronary syndrome (ACS) is frequently complicated by evidence of heart failure (HF). Those at highest risk for acute decompensated HF in the setting of ACS (ACS-HF) are older, female, and have preexisting heart disease, type 2 diabetes mellitus, hypertension, and/or kidney disease. The presenc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Heart failure 2022-06, Vol.10 (6), p.404-414
Hauptverfasser: Harrington, Josephine, Jones, W. Schuyler, Udell, Jacob A., Hannan, Karen, Bhatt, Deepak L., Anker, Stefan D., Petrie, Mark C., Vedin, Ola, Butler, Javed, Hernandez, Adrian F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Acute coronary syndrome (ACS) is frequently complicated by evidence of heart failure (HF). Those at highest risk for acute decompensated HF in the setting of ACS (ACS-HF) are older, female, and have preexisting heart disease, type 2 diabetes mellitus, hypertension, and/or kidney disease. The presence of ACS-HF is strongly associated with higher mortality and more frequent readmissions, especially for HF. Low implementation of guideline-directed medical therapy has further complicated the clinical care of this high-risk population. Improved utilization of current therapies, coupled with further investigation of strategies to manage ACS-HF, is desperately needed to improve outcomes in this vulnerable population, and the results of currently ongoing or recently concluded ACS-HF studies in this population are of great interest. In this review, we explore the pathophysiology, epidemiology, risk factors, and outcomes for patients with ACS-HF, and describe both existing evidence for management of this challenging condition and areas requiring further research. [Display omitted] •Acute decompensated heart failure in the setting of ACS is widely prevalent and associated with increased risk of both short- and long-term morbidity and mortality•Recent neutral findings for use of ARNI after MI underscore the need for dedicated trials exploring the efficacy of new GDMT therapies in the post-MI population•Future work is needed to improve implementation of existing therapies, and to identify new therapies for this high-risk group
ISSN:2213-1779
2213-1787
2213-1787
DOI:10.1016/j.jchf.2022.02.008